All In Biotech

Drug Trial Radar · NCT05478499

Efficacy and Safety of Deucravacitinib Versus Placebo in Participants With Moderate-to-severe Scalp Psoriasis

A Phase 3B/4, Multicenter, Randomized, Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Moderate-to-severe Scalp Psoriasis (PSORIATYK SCALP)

Last checked: Nov 20, 2026Latest source record: Oct 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 154 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

154

Actual

Start

Oct 6, 2022

Primary completion

Jan 11, 2024

Study completion Oct 17, 2024

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Jul 28, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the efficacy and safety of deucravacitinib to placebo in participants with moderate-to-severe scalp psoriasis.

Conditions

  • Psoriasis

Interventions

  • DeucravacitinibDrug

    Specified dose on specified days

  • PlaceboOther

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With a Scalp-specific Physician Global Assessment Score of 0 or 1 (Ss-PGA 0/1) at Week 16Time frame: Baseline and Week 16

Locations

29 sites in 5 countries. Site status is shown where the registry gives one.

  • Local Institution - 0001

    Hot Springs, Arkansas

  • Local Institution - 0007

    Indianapolis, Indiana

  • Local Institution - 0041

    Louisville, Kentucky

  • Local Institution - 0022

    Rockville, Maryland

  • Local Institution - 0008

    Beverly, Massachusetts

  • Local Institution - 0047

    Bloomfield Hills, Michigan

  • Local Institution - 0002

    New Brighton, Minnesota

  • Local Institution - 0049

    East Windsor, New Jersey

  • Local Institution - 0051

    Kew Gardens, New York

  • Local Institution - 0003

    Portland, Oregon

  • Local Institution - 0005

    Pittsburgh, Pennsylvania

  • Local Institution - 0033

    Houston, Texas

  • Local Institution - 0004

    San Antonio, Texas

  • Local Institution - 0006

    Norfolk, Virginia

  • Local Institution - 0019

    Paris, France

  • Local Institution - 0040

    Romans-sur-Isère, France

  • Local Institution - 0044

    Rouen, France

  • Local Institution - 0048

    Hamburg, Germany

  • Local Institution - 0012

    Lübeck, Germany

  • Local Institution - 0011

    Mahlow, Germany

  • Local Institution - 0038

    Witten, Deutschland, Germany

  • Local Institution - 0013

    Frankfurt am Main, Hesse, Germany

  • Local Institution - 0026

    Krakow, Poland

  • Local Institution - 0017

    Lodz, Poland

  • Local Institution - 0014

    Rzeszów, Poland

  • Local Institution - 0015

    Wroclaw, Poland

  • Local Institution - 0031

    London, Greater London, United Kingdom

  • Local Institution - 0045

    Salford, Greater Manchester, United Kingdom

  • Local Institution - 0039

    Southampton, HAMPSHIRE, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.